|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
GB9423172D0
(en)
*
|
1994-11-17 |
1995-01-04 |
Wellcom Foundation The Limited |
Hypolipidemic benzothiazepines
|
|
US6221897B1
(en)
|
1998-06-10 |
2001-04-24 |
Aventis Pharma Deutschland Gmbh |
Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
|
|
ATE240120T1
(en)
*
|
1998-12-23 |
2003-05-15 |
Searle Llc |
COMBINATIONS OF ILEUMGALLIC ACID TRANSPORT INHIBITORS AND FIBRONIC ACID DERIVATIVES FOR CARDIOVASCULAR INDICATIONS
|
|
EP1293211A1
(en)
*
|
1998-12-23 |
2003-03-19 |
G.D. Searle LLC. |
Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
|
|
HUP0105409A3
(en)
*
|
1999-02-12 |
2004-11-29 |
G D Searle Llc Chicago |
1,2-benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake, use thereof and pharmaceutical compositions containing them
|
|
SE0000772D0
(en)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
Chemical compounds
|
|
SE0003766D0
(en)
*
|
2000-10-18 |
2000-10-18 |
Astrazeneca Ab |
Novel formulation
|
|
EG26979A
(en)
|
2000-12-21 |
2015-03-01 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121337D0
(en)
|
2001-09-04 |
2001-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121622D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121621D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
AU2002329387B2
(en)
|
2001-09-08 |
2007-06-07 |
Albireo Ab |
Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia
|
|
GB0209467D0
(en)
|
2002-04-25 |
2002-06-05 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0213669D0
(en)
|
2002-06-14 |
2002-07-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0304194D0
(en)
|
2003-02-25 |
2003-03-26 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0307918D0
(en)
|
2003-04-05 |
2003-05-14 |
Astrazeneca Ab |
Therapeutic use
|
|
CA2683653A1
(en)
*
|
2007-04-10 |
2008-10-16 |
Boehringer Ingelheim International Gmbh |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
|
EP2367554A4
(en)
*
|
2008-11-26 |
2020-03-25 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of obesity and diabetes
|
|
EP4137137A1
(en)
|
2010-05-26 |
2023-02-22 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
|
RU2591188C2
(en)
|
2010-11-04 |
2016-07-10 |
Альбирео Аб |
Ibat inhibitor for treating hepatic disorders
|
|
MX369466B
(en)
|
2011-10-28 |
2019-11-08 |
Lumena Pharmaceuticals Inc |
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases.
|
|
US20140323412A1
(en)
|
2011-10-28 |
2014-10-30 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
|
|
KR20160002773A
(en)
|
2013-03-15 |
2016-01-08 |
루메나 파마수티컬즈, 인코포레이티드 |
Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
|
|
CA2907214A1
(en)
|
2013-03-15 |
2014-09-18 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
|
|
JO3301B1
(en)
|
2013-04-26 |
2018-09-16 |
Albireo Ab |
Crystal modifications of elobixibat
|
|
KR20220082931A
(en)
|
2014-06-25 |
2022-06-17 |
이에이 파마 가부시키가이샤 |
Solid preparation, and method for preventing or reducing discoloration thereof
|
|
EP3012252A1
(en)
|
2014-10-24 |
2016-04-27 |
Ferring BV |
Crystal modifications of elobixibat
|
|
US10786529B2
(en)
|
2016-02-09 |
2020-09-29 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US10441604B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Cholestyramine pellets and methods for preparation thereof
|
|
US10441605B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
CA3071285A1
(en)
|
2017-08-09 |
2019-02-14 |
Albireo Ab |
Cholestyramine granules, oral cholestyramine formulations and use thereof
|
|
ES2942443T3
(en)
|
2018-06-05 |
2023-06-01 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
US10793534B2
(en)
|
2018-06-05 |
2020-10-06 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
US11801226B2
(en)
|
2018-06-20 |
2023-10-31 |
Albireo Ab |
Pharmaceutical formulation of odevixibat
|
|
SG11202012151XA
(en)
|
2018-06-20 |
2021-01-28 |
Albireo Ab |
Crystal modifications of odevixibat
|
|
US10722457B2
(en)
|
2018-08-09 |
2020-07-28 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US11007142B2
(en)
|
2018-08-09 |
2021-05-18 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US11549878B2
(en)
|
2018-08-09 |
2023-01-10 |
Albireo Ab |
In vitro method for determining the adsorbing capacity of an insoluble adsorbant
|
|
CN113677398B
(en)
|
2019-02-06 |
2024-07-23 |
阿尔比里奥公司 |
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
US10941127B2
(en)
|
2019-02-06 |
2021-03-09 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
US10975045B2
(en)
|
2019-02-06 |
2021-04-13 |
Aibireo AB |
Benzothiazepine compounds and their use as bile acid modulators
|
|
FI3923943T3
(en)
|
2019-02-12 |
2024-09-19 |
Mirum Pharmaceuticals Inc |
Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
|
|
CN111808045B
(en)
*
|
2019-04-12 |
2022-07-08 |
中国科学院大连化学物理研究所 |
Method for synthesizing chiral seven-element cyclic sulfonamide through organic catalysis
|
|
US11014898B1
(en)
|
2020-12-04 |
2021-05-25 |
Albireo Ab |
Benzothiazepine compounds and their use as bile acid modulators
|
|
WO2021110885A1
(en)
*
|
2019-12-04 |
2021-06-10 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
JP2023504643A
(en)
|
2019-12-04 |
2023-02-06 |
アルビレオ・アクチボラグ |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
CN114786772B
(en)
|
2019-12-04 |
2024-04-09 |
阿尔比里奥公司 |
Benzothiazepine compounds and their use as bile acid modulators
|
|
JP2023504644A
(en)
|
2019-12-04 |
2023-02-06 |
アルビレオ・アクチボラグ |
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
PH12022551085A1
(en)
|
2019-12-04 |
2024-06-19 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
CA3186857A1
(en)
|
2020-08-03 |
2022-02-10 |
Per-Goran Gillberg |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
AU2021379076A1
(en)
|
2020-11-12 |
2023-06-08 |
Albireo Ab |
Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
|
|
BR112023010799A2
(en)
|
2020-12-04 |
2023-10-03 |
Albireo Ab |
BENZOTIA(DI)AZEPINE COMPOUNDS AND THEIR USES AS BILLARY ACID MODULATORS
|